CPC C07K 16/28 (2013.01) [C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/30 (2013.01); A61K 35/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] | 31 Claims |
1. A method of reducing mesothelin-expressing tumor burden in a subject and/or increasing survival of a subject having a mesothelin-expressing neoplasm, comprising administering to the subject in need thereof an effective amount of T cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain specifically binds to human mesothelin comprises: (a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13; and (b) a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 16.
|